May-April 2008

2007-2006

All News On HCV

We have a member on our site that participated in the Vertex Trial.

Denise Treating With Protease Inhibitor Telaprevir Vertex-950

HCV Protease Inhibitor Telaprevir, PROVE1 Study: final results of a phase 2 study with peginterferon plus ribaviron in treatment-naive patients with hepatitis C -

HCV Protease Inhibitor Telaprevir, PROVE1 Study: final results of a phase 2 study with peginterferon plus ribaviron in treatment-naive patients with hepatitis C

A Study of Telaprevir (TVR) with Peginterferon Alfa-2a (P) and Ribavirin (R) in Subjects with Well-Documented Prior PR Null Response, Non-Response or Relapse: Preliminary Results

Vertex and Tibotec Start Phase 3 Study of Telaprevir for Treatment-Naive Genotype 1 Hepatitis C Patients

Telaprevir plus Pegylated Interferon and Ribavirin Allows Shorter Therapy for Patients with Genotype 1 HCV

Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment

Vertex reports promising hepatitis C drug results

Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments

Vertex Telaprevir HCV Protease Inhibitor Could Be A Winner; 2.5 million untreated/undiagnosed

New HCV Protease Inhibitor Telaprevir: 80% of Treatment-Experienced Patients Achieve Early Viral Response

Vertex to Start Phase 3 Trials of HCV Protease Inhibitor Telaprevir (VX-950) - 2/01/08

Data On Investigational Compounds Being Co-Developed By Tibotec For The Treatment Of Chronic Hepatitis C Presented At EASL 2008

Denise's Story

Read more on our message boards

The whole story

I can't believe I only have 3 days of Riba left!  It was so great to fill up my pill dispenser for the week and be able to leave some days empty!!! 

It's been a rough ride(who's treatment isn't?!?) but if I can hold onto that UD it will all have been worth it.

Iam1a, Stage2, Grade 1-2.  I was in a 48 week arm.  The first 24 weeks I took the standard treatment as well as the Telaprevir.  The last 24 weeks have been standard treatment only.

They did not allow rescue drugs in the Prove 3 trial and I became anemic real quick...just like the last time I treated.  Since Procrit wasn't an option they had to dose reduce/discontinue my Riba for most of the trial.  I was only on full dose Riba for a few of the 48 weeks.  It's been shown that Riba is a necessary part of the cocktail so I was VERY nervous.  I wasn't able to get any VL results until my 24 week results.  At that time I found out that I went from 12,500,000 on my start date to <30 by week 4! The first time I treated with SOC I didn't have a 2 log drop by week 13 and stopped.  At that time  I started with a much lower VL of 2,380,000.  That just give's you an idea of how powerful these PI's are.

Vertex is continuing trails with the Telaprevir as well as 2 other PI's.

Vertex has submitted some late extracts regarding Prove 3 preliminary results to be presented at the EASL meeting in April.  I have a feeling it's going to be more great news from Vertex. 

I learned everythingI needed to get me through the past 48 weeks right here on J&F and will always be grateful for this site and the people here.

I owe Karen a huge debt of gratitude.  She has been there for me every day and when I didn't feel like talking to ANYONE, Karen was the exception.  Thank you my friend.  Now, we need to get you on a PI so we can start planning that trip!

A friend of mine has declared Thursday as "All bad things gone and only good things to come,day!";-)

Thanks again to everyone for the well wishes and hope to start posting again as my system starts to clear.

If anyone has any questions about the Prove 3 trail feel free to email me through my profile.

BTW, I LOVE VERTEX!!!

Denise...next stop SVR...

UPDATE April 30th 08

2007-2006

Telaprevir plus Pegylated Interferon Is Effective against Both Wild-type and Drug-resistant HCV Strains   - 8/17/07

Mutations That Confer Resistance to HCV Protease Inhibitors 5/01/07

Telaprevir-based Therapy for HCV May Shorten Treatment Duration from 48 to 24 Weeks for Some Genotype 1 Patients - 4/17/07

In Vitro Studies Suggest Promising Outcomes with New HCV Protease Inhibitor ACH 806 in Combination with Interferon, Telaprevir, or NM 107 4/05/07

Telaprevir Demonstrates Safety and Anti-HCV Activity in 12-week Interim Analysis 1/05/07

Telaprevir Resistance Mutations Observed in Laboratory Studies  12/05/06

Updated Results from Patients Receiving Standard HCV Therapy Following Telaprevir  12/01/06

Telaprevir plus Pegylated Interferon Suppresses Wild-type and Resistant HCV Over 14 Days  11/03/06

Rapid Decline of HCV RNA in Patients Treated with VX-950 10/02/06

12 of 12 Patients Receiving Experimental HCV Protease Inhibitor VX 950 in Combination with Pegasys Plus Ribavirin for 28 Days Experience Undetectable HCV RNA Levels- 5/23/06

Small Study Shows HCV RNA Levels Undetectable in 12 of 12 HCV Genotype 1 Patients after 4 Weeks of Treatment with Experimental HCV Drug VX 950 Plus Pegasys and Ribavirin - 2/10/06

Experimental Oral Protease Inhibitor VX-950 from Vertex Produces Rapid and Dramatic Reduction in HCV RNA in Combination with Pegylated Interferon Alfa-2a (Pegasys) - 1/10/06